These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36633811)

  • 41. Givosiran - Running RNA Interference to Fight Porphyria Attacks.
    Gonzalez-Aseguinolaza G
    N Engl J Med; 2020 Jun; 382(24):2366-2367. PubMed ID: 32521139
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluating the Efficacy of a Small Interfering Ribonucleic Acid Molecule, Givosiran, in Treating Acute Intermittent Porphyria: A Systematic Review.
    Patel P; Midha S; Shukla S; Dhamija D; Bello AO; Khan S
    Cureus; 2023 Jun; 15(6):e40585. PubMed ID: 37469824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurology of the acute hepatic porphyrias.
    Oliveira Santos M; Leal Rato M
    J Neurol Sci; 2021 Sep; 428():117605. PubMed ID: 34375916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
    Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
    Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
    Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
    J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
    Kamal MA; Van Wart SA; Rayner CR; Subramoney V; Reynolds DK; Bulik CC; Smith PF; Bhavnani SM; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3470-7. PubMed ID: 23669384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
    Holm A; Løvendorf MB; Kauppinen S
    Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.
    Chan P; Li H; Zhu L; Bifano M; Eley T; Osawa M; Ueno T; Hughes E; Bertz R; Garimella T; AbuTarif M
    Clin Pharmacokinet; 2017 Oct; 56(10):1173-1183. PubMed ID: 28066880
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
    Adedokun OJ; Xu Z; Gasink C; Kowalski K; Sandborn WJ; Feagan B
    Clin Ther; 2022 Oct; 44(10):1336-1355. PubMed ID: 36150926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.
    Goel V; Hurh E; Stein A; Nedelman J; Zhou J; Chiparus O; Huang PH; Gogov S; Sellami D
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):745-55. PubMed ID: 26898300
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine.
    Zhou W; Li J; Birmingham B; Xu H; Lillieborg S; Zhou D; Al-Huniti N
    J Clin Pharmacol; 2017 Oct; 57(10):1258-1267. PubMed ID: 28581633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
    Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
    Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria].
    Stölzel U
    Z Gastroenterol; 2020 Aug; 58(8):785. PubMed ID: 32785915
    [No Abstract]   [Full Text] [Related]  

  • 54. Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1).
    Lazareth H; Poli A; Bignon Y; Mirmiran A; Rabant M; Cohen R; Schmitt C; Puy H; Karras A; Gouya L; Pallet N
    Kidney Int Rep; 2021 Jul; 6(7):1904-1911. PubMed ID: 34307985
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP.
    Baudry E; Huguet S; Couderc AL; Chaibi P; Bret F; Verny C; Weill S; Madar O; Urien S; Rezai K
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):775-785. PubMed ID: 30689002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma.
    Yamamoto Y; Sanwald Ducray P; Björnsson M; Smart K; Grimsey P; Vatakuti S; Portron A; Massonnet B; Norris DA; Silber Baumann HE
    CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1213-1226. PubMed ID: 37221972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population pharmacokinetics of lamotrigine in Indian epileptic patients.
    Mallaysamy S; Johnson MG; Rao PG; Rajakannan T; Bathala L; Arumugam K; van Hasselt JG; Ramakrishna D
    Eur J Clin Pharmacol; 2013 Jan; 69(1):43-52. PubMed ID: 22660444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.
    Peigné S; Fouliard S; Decourcelle S; Chenel M
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):29-43. PubMed ID: 26578442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
    Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L
    J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.